{ "id": "abo-blood-group-system", "title": "ABO Blood Group System", "lang": "en", "source_lang": "en", "summary": "The ABO blood group system classifies human blood into A, B, AB and O by red-cell carbohydrate antigens and naturally occurring antibodies, and underlies transfusion compatibility.", "category": "science", "subcategory": "biology", "type": "concept", "aliases": [ "ABO blood group", "ABO blood typing", "ABO system" ], "generated_at": "2026-10-08", "model": "pro/claude-haiku-5-5", "url": "https://aiwiki.page/en/abo-blood-group-system/", "translations": { "zh-Hans": { "url": "https://aiwiki.page/zh/abo-blood-group-system/", "json": "https://aiwiki.page/zh/abo-blood-group-system.json" } }, "sections": [ { "heading": "", "text": "The ABO blood group system is the most important classification of human blood types in transfusion medicine. It divides people into four groups, A, B, AB and O, according to which carbohydrate antigens (antigens) are present on the surface of their red blood cells. Each group also carries antibodies against the antigens it lacks, which are present without any known prior exposure. Because these antibodies can destroy mismatched red cells, the system determines which blood can safely be given to which person. The antigens are built on the H substance by enzymes encoded by a single gene on chromosome 9, and their inheritance follows a simple pattern of multiple alleles, which makes the system a standard example in genetics as well.\n\nThe system was discovered by Karl Landsteiner in Vienna around 1900–1901, after he found that the serum of some people clumped the red cells of others. This work led to the 1930 Nobel Prize in Physiology or Medicine and to the systematic study of human blood variation. Since then, ABO has become the reference against which other blood group systems are compared, and its role has expanded from transfusion and transplantation into population genetics, evolutionary biology, and epidemiology, where it has been linked to differences in the risk of several cardiovascular diseases, cancers and infections.\n\nThis entry first defines the system and traces its discovery, then explains the biochemical and genetic basis of the antigens and the origin of the naturally occurring antibodies. It next covers population frequencies and evolutionary hypotheses, followed by the clinical applications in transfusion, transplantation and pregnancy. The entry then reviews the disease associations reported in the literature, the methods used for typing and standardization, and the questions that remain open." }, { "heading": "Definition and Basic Classification", "text": "Definition\n\nThe ABO system sorts human red blood cells by two linked features: whether the cell carries the A antigen, the B antigen, both or neither, and which antibodies circulate in the plasma. Plasma antibodies are always directed against the antigen the individual lacks, because the immune system is tolerant of the antigens a person carries. The ABO antigens are carbohydrate structures, so their specificity depends on the arrangement of sugar residues rather than on a protein sequence. This is the main chemical feature that separates ABO from most other systems. The genetic basis (a single gene at the ABO locus on chromosome 9, with the A, B and O alleles) is treated in the genetics section; here the focus is on the phenotypic classification used in clinical practice.\n\nThe Four Phenotypes\n\nThe four phenotypes follow directly from the combinations of antigen and antibody:\n\nPhenotype | Antigens on red cells | Plasma antibodies | Notes\nA | A | anti-B | Subgroups A1 and A2 differ in antigen density\nB | B | anti-A |\nAB | A and B | neither anti-A nor anti-B | Lacks both antibodies\nO | Neither A nor B | anti-A and anti-B | Also carries an anti-A,B reactivity in some typing systems\n\nBlood group O is the most common phenotype in most populations, while AB is the rarest in most samples. In a 2,043-donor study, the observed distribution was O 36.5%, B 26.7%, A 23.2% and AB 13.6%, though frequencies vary considerably between populations. The A phenotype is further divided into A1 and A2, with A1 accounting for the large majority of A-group individuals. The antibodies are mainly of the IgM class, which is why they react efficiently at room temperature, whereas the antibodies produced against Rh or Kell antigens are typically IgG.\n\nHow ABO Differs from Other Systems\n\nThe International Society of Blood Transfusion (ISBT) recognizes a growing number of blood group systems, with sources citing 43 systems in one count and 48 in a later one; the discrepancy reflects differing update dates. Besides ABO, the list includes Rh, Kell, Duffy, Kidd, MNS, P, Lewis and Lutheran. ABO is the oldest of these systems and is widely regarded as the most important clinically. Several features set it apart:\n\n- Antigen chemistry. ABO antigens are oligosaccharides attached to proteins and lipids on the cell membrane. Rh, Kell, Duffy and MNS specificities are generally determined by amino acid sequences.\n- Antibody origin. Anti-A and anti-B are naturally occurring, meaning people develop them without any known transfusion or pregnancy. Most antibodies against Rh, Kell or Duffy antigens are immune antibodies, formed after exposure to foreign red cells.\n- Relationship to H. The A and B antigens are built on the H structure. Although ABO and H are separate genetic systems, they are commonly described together because of this biochemical dependence.\n\nTerminology: Blood Group Versus Blood Type\n\nThe ISBT glossary defines a blood group as a classification based on the presence or absence of specific antigens on red cell surfaces. A blood type, by contrast, is an individual's particular combination of those antigens, most commonly described using ABO and Rh status (for example, A positive or O negative). In everyday practice, however, ISBT notes that the two terms are often used interchangeably, and the distinction is not always observed in clinical or scientific writing.\n\nInternational Standardization\n\nEarly naming was inconsistent. Antigens received alphabetical labels or were named after the antibody or the patient who produced it. In 1980 the ISBT established a working party to devise a genetically based numerical terminology. Under this scheme each system has a number and a symbol: ABO is system 001 with the symbol ABO, and Kidd is 009 with the symbol JK. Antigens within each system are numbered in order of discovery, and low- and high-prevalence antigens are grouped into the 700 and 900 series. The numerical form was designed mainly for computer input, so everyday usage relies on shorter alternative names. For example, the O phenotype is written in ISBT phenotype notation as ABO:-1,-2,-3,-4, where the minus sign indicates an absent antigen. The ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology continues to maintain these guidelines and to assign newly recognized antigens to the appropriate systems." }, { "heading": "Discovery and Early Development", "text": "Landsteiner's agglutination experiments\n\nKarl Landsteiner, a pathologist at the Pathological-Anatomical Institute of the University of Vienna, found the first human blood groups by mixing the serum of one person with the red cells of another. Serum from some people clumped the red cells of certain others, but not all. In a footnote in 1900, he noted that human serum agglutinated the cells of other humans, which was the first mention of human isoantibodies. By late 1901 he had published the full experimental evidence, including a cross-test of the red cells and sera of six people, himself included. He concluded that the reactions reflected individual differences rather than disease alone. Those results appeared in the paper \"Über Agglutinationserscheinungen normalen menschlichen Blutes\" in the Wiener klinische Wochenschrift.\n\nHis first scheme had three groups, initially called A, B and C. Serum from group A agglutinated the red cells of group B, and serum from group B agglutinated those of group A. Group C serum agglutinated the cells of both A and B, while its own red cells were not clumped by either A or B serum. Landsteiner therefore inferred that the sera contained at least two kinds of agglutinins, one in A, one in B, and both together in C. In his scheme, the terms \"agglutinogens\" and \"agglutinins\" described what are now called antigens and antibodies.\n\nIdentification of AB and the 1910 nomenclature\n\nIn 1902, his colleagues Alfred von Decastello and Adriano Sturli, working with a larger group of volunteers, identified the fourth combination, now called AB, which carries both A and B antigens and has neither of the corresponding antibodies. Landsteiner's C group was later renamed O, because its red cells carry neither antigen.\n\nThe modern letter nomenclature was set in 1910 by Emil von Dungern and Ludwik Hirszfeld in Heidelberg. They named the four groups A, B, AB and O, and they designated the agglutinins as anti-A and anti-B. Hirszfeld and von Dungern also observed that the groups were not mutually exclusive in the sense that a person could have both A and B features. The name \"AB\" reflects the simultaneous presence of both antigens. In 1928, a standardization committee of the League of Nations Hygiene Committee accepted the A, B, O scheme proposed by von Dungern and Hirszfeld, and it remains in use.\n\nNobel recognition and the question of dates\n\nLandsteiner received the Nobel Prize in Physiology or Medicine in 1930 for his discovery of human blood groups, and the Nobel Foundation describes the work as having greatly reduced the risk of transfusion. Sources differ on the year of discovery. Many give 1900, reflecting the footnote in which he first described human isoagglutination, while others give 1901, the year of his full publication. Some give 1900–1901 as a range. The discrepancy is largely a matter of which publication is taken as the discovery.\n\nGenetic hypotheses and biochemical specificity\n\nFor decades after the discovery, geneticists debated how the groups were inherited. Two models competed. One proposed multiple alleles at a single locus. The other proposed two independent loci with two alleles each: one determining A versus non-A and the other B versus non-B. Felix Bernstein applied the Hardy–Weinberg principle to population data, and analysed family data, and concluded that the single-locus, multiple-allele model fit the data while the two-locus model did not. Bernstein's 1924 and 1925 papers were central to this, and in 1934 Lionel Penrose used his own ABO data to support the allelomorphic view. Later, in the 1950s and 1960s, researchers identified the biochemical basis of ABO specificity: the A and B alleles encode glycosyltransferase enzymes that add different sugars to a common precursor on the cell surface. These findings replaced the phenotype-based model with a molecular one." }, { "heading": "Biochemical Basis: Antigens and Glycosyltransferases", "text": "The H precursor and the A and B transferases\n\nABO antigens are carbohydrate structures, and they are built in stages on a shared scaffold. That scaffold is the H antigen, a precursor chain of galactose and N-acetylglucosamine to which a fucose is joined in an α(1,2) linkage by a fucosyltransferase The precursor oligosaccharide chain containing Galactose (Gal) and N-Acetylglucosamine (GlcNAc) is further linked to a fucose (Fuc), by an α(1,2) fucosyltransferase FUT1 enzyme (encoded by H-gene), to form an H antigen. The H gene lies on chromosome 19 and its product is most active in erythroid cells, the precursors of red blood cells The gene H(FUT1) on chromosome 19 encodes a fucosyltransferase preferentially expressed in erythroid cells.\n\nThe A and B enzymes, which are glycosyltransferases, then extend this H structure with a second sugar. The A enzyme attaches N-acetylgalactosamine and the B enzyme attaches D-galactose, both through an α1,3 bond The A and B enzymes catalyze the transfer of an N-acetylgalactosamine and a galactose, respectively, in α1,3 linkage on a precursor structure called the H antigen. The synthesis takes place in the Golgi apparatus, where the enzymes transfer the appropriate sugar onto an oligosaccharide acceptor The antigenic determinants are synthesized in the Golgi apparatus by specific glycosyltransferases which transfer proper sugars to an oligosaccharide acceptor, called H antigen.\n\nThe two enzymes differ at only four amino acid positions in their catalytic domain, and two of these, positions 266 and 268, mainly determine substrate specificity There are only four amino acid differences between A and B transferases in the catalytic domain, two of which (Leu266Met and Gly268Ala) are primarily responsible for the substrate specificity. Structural studies explain the B enzyme's failure to bind GalNAc by the presence of bulky side chains at these positions the presence of amino acids with bulky side chains (methionine and alanine) in transferase B cause its inability to bind N-acetylgalactosamine.\n\nCarbohydrate chains as the molecular form of the antigens\n\nThe ABO gene encodes an enzyme, not the antigen itself. The antigens are secondary products of the gene, since the enzymes add monosaccharides to an oligosaccharide backbone that is anchored to proteins or lipids Like carbohydrates, antigens A and B are secondary products of the ABO gene, which primarily encodes specific enzymes that catalyze the addition of monosaccharide motifs to an oligosaccharide backbone anchored to glycoproteins or glycolipids through N- or O-linked glycosylation. The terminal sugar is therefore the epitope that antibodies recognize, while the protein or lipid acts as a carrier. This is why the antigen is defined by sugar structure rather than by peptide sequence. Each cell membrane carries a large number of these sites: Each RBC carries over 2 million ABH antigen sites.\n\nWhy group O lacks A and B\n\nGroup O individuals have alleles that produce no working transferase. The most common such allele carries a single-base deletion in exon 6. The main cause for the inactive ABOO.01.01 allele is a guanine deletion at nt position 261 in exon 6 (c.261delG) in a sequence that otherwise is identical to the consensus ABOA1.01 allele. Because the deletion shifts the reading frame, a truncated protein is produced: The truncated, 155 amino acid protein encoded by the O allele lacks the functional domain of the transferase. Some older reports number this same deletion as position 258 of the coding sequence, so the two numbering systems should not be confused At position 258 of the coding sequence, the O allele differs from the A and B alleles by a single base pair deletion, which, due to the resulting frameshift in translation, creates a stop codon at nucleotides 349-351. Other O alleles are inactivated by different mutations, such as a missense change at codon 268 a single inactivating glycine-to-arginine substitution at codon 268 (Gly268Arg) in the AT background in some O alleles. Since none of these alleles yields a working enzyme, the H structure is left intact Individuals with blood type O lack a functional glycosyltransferase and express only the unmodified H antigen on cell surfaces.\n\nExpression beyond red cells\n\nABO antigens are not confined to red cells. In secretions, the expression depends on a separate fucosyltransferase, FUT2, which is active in epithelial cells. People with an active FUT2 gene (secretors) make H on type 1 chains in secretions and then convert it to A or B if they carry the relevant transferase Individuals who have an active Se(FUT2) are termed ABO secretors because they produce the fucosyltransferase enzyme responsible for the H antigen on type 1 glycoproteins, which are produced in epithelial cells and whose products reside on mucins in secretions. Having synthesized H in secretions, they subsequently convert the H antigen to A and B in the presence of the appropriate transferases. The antigens are also found on the endothelial and epithelial cells of the lung, gut, urinary tract and reproductive tract, which is why they are called histo-blood group antigens ABH antigens are also found on other tissues, including endothelial and epithelial cells of the lung, gut, and urinary and reproductive tracts (and are therefore termed histo-blood group antigens).\n\nPlatelets carry ABH structures on both glycoproteins and glycolipids, and this expression appears to be dosage-dependent. Platelet A antigen levels were significantly higher in A1A1 homozygotes than in A1O1 heterozygotes In keeping with the concept that there is a dosage effect of the ABO locus on enzymatic activity, platelet A antigen expression was significantly higher in homozygous A^1A^1 compared to heterozygous A^1O^1 individuals. Plasma von Willebrand factor carries ABO determinants too, but the pattern differs: although H antigen is expressed on platelet-derived VWF, there is no A or B antigen expression." }, { "heading": "Genetics of the ABO Locus", "text": "Gene location and allele structure\n\nThe ABO gene sits on the distal long arm of chromosome 9 at band 9q34.2. It encodes a transferase enzyme responsible for determining blood group antigens, consisting of 7 exons and spanning more than 18 kilobases. The two largest exons, 6 and 7, include 77% of the full coding region and encode all of the catalytic domain. The A and B transferases are nearly identical; the encoded protein is 354 amino acids long, and the A and B forms differ at only four of those positions. Most of the variation between the common forms therefore lies in exons 6 and 7.\n\nEach person carries two copies of the locus, one inherited from each parent. Over 200 alleles have been described at the ABO locus, with three common A, B, and O alleles observed. The International Society of Blood Transfusion (ISBT) maintains the official allele table, which is mostly based on exonic variation; intronic changes are largely not included in its nomenclature.\n\nCodominance, recessiveness and genotype–phenotype relationships\n\nThe A and B alleles are codominant, while O is recessive. Alleles A and B are codominant over allele O and determine the expression of the homonymous antigens. With three alleles, six genotypes are possible, but only four phenotypes result.\n\nGenotype | Phenotype | Antigens on red cells\nAA, AO | A | A\nBB, BO | B | B\nAB | AB | A and B\nOO | O | Neither (H only)\n\nThe O allele is a loss-of-function variant. Its best-known form is a single-base deletion in exon 6 that shifts the reading frame, so the protein made is almost entirely different and lacks transferase activity. Because O produces no working enzyme, the H structure on the cell surface remains unmodified.\n\nSubgroups, weak alleles and cis-AB\n\nMost A phenotypes belong to two main subgroups. A1 and A2 phenotypes account for ~99% of \"A\" antigen phenotypes, and the rest are weaker variants (e.g., Ax, A3, etc.). The A2 allele is typically defined by a single-base deletion (c.1061delC) in exon 7, which causes a frameshift near the C-terminus. This change produces both a qualitative and quantitative difference between A1 and A2.\n\nMany other alleles weaken antigen expression through single amino acid substitutions or other small changes. A 2001 sequencing study of individuals with atypical serology revealed 15 novel A and B subgroup alleles. These included 2 which were the first examples of mutations outside exon 7 associated with weak subgroups. Serologically, weak subgroups are usually classified in two ways: type II (weak/missing antigen) or type IV (due to presence of Anti–A1) ABO discrepancy.\n\nA particularly important variant is cis-AB, in which the A and B alleles lie on the same chromosome. This chromosome is usually transmitted together with an O allele from the other parent. Its molecular basis, as described in the literature, includes unequal crossing-over and point mutations in the A allele. In the category of weak/missing red cell reactivity, ABO subgroup was the most common reason, and using ABO genotyping, 26.2 % of the cases genotyped were found to be related to the cis-AB allele. Because it can look like a simple AB or a weak B, cis-AB is a frequent source of transfusion-relevant errors.\n\nGenetic typing versus serological phenotyping\n\nRoutine ABO typing is serological: red cells are tested with anti-A and anti-B reagents, and the presence or strength of agglutination defines the phenotype. This approach is fast, but it cannot always distinguish weak or atypical alleles. Genotyping instead uses polymerase-chain-reaction amplification followed by dna-sequencing of the exons, usually exons 6 and 7, or of the whole gene where needed. All exons of ABO were amplified by PCR and sequenced using Sanger sequencing.\n\nThe two methods often disagree in clinical samples. In a study of kidney transplant candidates with grouping discrepancies, ABO gene sequencing revealed that all the 302 candidates carried weak ABO alleles, leading to grouping discrepancies observed in the reciprocal serotyping. A Chinese study of A2 individuals reported a much higher discrepancy rate, 42.38%, between serotyping and genotyping in one cohort, and found that individuals with the same genotype could show different agglutination strength.\n\nDiscrepancies are explained in several ways. Weak alleles, cis-AB haplotypes and the presence of anti-A1 in the serum can each lead to mismatched results. Some discordances are harder to explain. In one family, the child and both parents carried A alleles at the genetic level, yet antigen expression was weak or undetectable serologically. The authors proposed epigenetic hypermethylation of the promoter as one possible cause, although this remains a hypothesis. Genotyping is therefore increasingly used to resolve difficult cases, particularly before transfusion or transplantation, where misclassification can lead to serious consequences, such as hemolytic adverse transfusion reactions." }, { "heading": "Population Frequencies and Evolutionary Origins", "text": "Geographic variation and how frequencies are estimated\n\nThe three ABO alleles occur at very different frequencies from one region to another. A retrospective study of about 40,000 people from five Bhutanese hospitals put the A, B and O alleles at roughly 0.23, 0.18 and 0.59, with the O phenotype the most common. A larger sample from Lagos, Nigeria, collected between 1998 and 2009, gave allele frequencies of about 0.14 for A, 0.13 for B and 0.73 for O (the study followed a population across an 11-year period; A, B and O were estimated at 0.14, 0.13 and 0.73). These figures differ because local populations have different histories, not because the system itself varies in structure.\n\nAllele frequencies cannot be read directly from routine typing, because serology reveals phenotypes rather than genotypes. Blood-bank surveys therefore count the four phenotypes and convert those counts into allele frequencies with a statistical model. In one Jordanian donor sample of 12,215 people, the frequencies of the I^o, I^a and I^b alleles were calculated using the Hardy-Weinberg law, yielding about 0.605 for O, 0.261 for A and 0.134 for B.\n\nHardy–Weinberg models and deviations\n\nThe model is the Hardy–Weinberg equilibrium. If p, q and r are the frequencies of the A, B and O alleles, the expected phenotype frequencies are \\(p^2 + 2pr\\) for A, \\(q^2 + 2qr\\) for B, \\(2pq\\) for AB and \\(r^2\\) for O. Inverting these expressions gives a direct estimate: \\(r = \\sqrt{O}\\), \\(p = \\sqrt{A+O} - \\sqrt{O}\\) and \\(q = \\sqrt{B+O} - \\sqrt{O}\\), where each capital letter is an observed phenotype frequency. Applied to the Jordanian counts (O ≈ 0.366, A + O ≈ 0.750, B + O ≈ 0.547), these formulas reproduce the reported allele values. Systematic departures from the expected genotype distribution are then used to detect problems such as non-random mating, population substructure, sampling bias among donors, or selection. Donor samples are not always representative, so such tests are interpreted cautiously.\n\nHistorical population movements also reshape allele frequencies, a process driven by gene flow and genetic drift. Ancient DNA from Hokkaido shows that the East Asian A allele was observed in both Jomon/Epi-Jomon (0.182) and Okhotsk people (0.038), which contrasts with the modern values of about 0.19 in Japanese and 0.19 in Han populations. Such contrasts show how small, isolated groups and admixture can shift frequencies over only a few millennia.\n\nPathogen-driven balancing selection\n\nThe idea that infectious disease maintains ABO diversity is long-standing. An association between ABO and infectious diseases like cholera was identified by early etiological studies, and one account argues that the major variations observed in ABO blood groups in different parts of the world were due to the epidemics of the past. A specific mechanism was proposed: a plague and cholera bacterium carrying an H-like antigen, and a smallpox virus carrying an A-like antigen, could favor different antibody profiles, so that individuals who can make anti-H (A1 and B) would be more resistant to the plague and cholera. Because the cholera association rests mainly on early studies, it remains a hypothesis rather than an established result.\n\nThe best-supported case concerns malaria. A large case-control study found that alleles producing functional ABO enzymes are associated with greater risk of severe malaria phenotypes (particularly malarial anemia) in comparison with the frameshift deletion underlying blood group O. Population data also show a region of low F(ST) across the ABO locus between the three main HapMap population groups, which the authors interpret as a signal of long-standing balancing selection at the ABO locus, caused by multiple infectious pathogens including P. falciparum. Not all studies agree on direction: one report found that the subjects with non-O blood were less susceptible to malaria infection. The O allele may therefore protect against severe disease while the effect on infection is weaker or reversed. Other workers have suggested that gut pathogens may have exerted pressures comparable to malaria.\n\nSeveral arguments count against a simple pathogen explanation. A classic mechanism for long-term maintenance, heterozygote advantage, may be unlikely to underlie long-lived balancing selection, instead representing a transient solution. Moreover, since ABO polymorphism appears across many primates, the selected phenotype is probably not tied to the expression of antigens on red blood cells, a trait restricted to Hominoids. Any pathogen hypothesis must therefore explain a selective pressure that operated across very different lineages.\n\nTrans-species polymorphism and deep origins\n\nABO polymorphism is considerably older than modern humans. Analyses of sequence data have shown that ABO is a trans-species polymorphism inherited identical by descent in humans and gibbons as well as among all Old World monkeys studied. Earlier, arguably the best studied case of apparent convergent evolution had been the ABO system, with the consensus favoring independent origins of the A and B antigens. The authors argue that genetic variation data in humans and gibbons as well as in Old World monkeys are inconsistent with a model of convergent evolution. A PCR-based study had earlier placed the critical substitutions before the divergence of the lineages leading to humans, chimpanzees, gorillas, and orangutans, which implies an age of at least 13 million years for the polymorphism. The most recent estimate is that the ABO polymorphism is a trans-species polymorphism among distantly related species and has remained under balancing selection for tens of millions of years.\n\nWithin this shared framework, alleles have been gained and lost in different lineages. Although one of the alleles has been lost in some lineages during great ape speciation, other lineages have retained both the A and B identical-by-descent alleles. Among the species examined, 19 of the 40 species studied have both A- and B-type alleles. Human AB individuals usually carry two separate alleles, but rare cis-AB haplotypes can produce the AB phenotype on a single chromosome; these have not reached fixation in any of the surveyed species and are rare in humans. Present-day frequencies therefore reflect ancient balancing selection, subsequent demographic events, and the continuing effects of drift and migration." }, { "heading": "Naturally Occurring Antibodies and Immune Mechanisms", "text": "People whose red cells lack the A or B antigen usually have plasma antibodies against the missing antigen, although they have never been transfused or deliberately immunized. Landsteiner proposed that these antibodies could arise in two ways, partly triggered by antigen and partly spontaneously, and the question of their origin has remained open ever since. It had been proposed by Landsteiner that natural antibodies had a dual origin, antigen-induced and spontaneous.\n\nOrigin: the microbiota hypothesis\n\nThe leading explanation is that the immune system is primed by microorganisms. The ABO antigens are carbohydrates, and many bacteria in the gut carry structurally similar sugar chains. Anti-A and anti-B antibodies are therefore thought to form in response to these microbial look-alikes. The origin of ABO antibodies is still controversial, however, their synthesis seems to be mostly triggered by either microbiota or pathogenic microorganisms bearing ABO(H)-like antigens. The timing fits this idea: antibodies form after exposure to ABH-like substances from the gastrointestinal tract, beginning in utero or immediately after birth, and peak at about 5 to 10 years of age. Colonization of the infant gut right after birth is one candidate source of this exposure. Some authors go further and argue that carbohydrate-specific antibodies generally arise after immune cells meet the intestinal microbiota, rather than in the absence of any antigen.\n\nThe mechanism remains partly hypothetical. A 2023 commentary noted that although the timing of antibody production is well documented, its dependency on exposure to microbial antigenic determinants is still hypothetical. Subsequent work in a mouse model examined the roles of CD4+ T cells, the microbiota and sex in the development of anti-A antibodies. Anti-A,B cross-reacting antibodies, which react with both antigens, are a further complication. They have been reported mainly in group O individuals, and the existence of anti-A,B has been difficult to prove because of contamination of test cells with small amounts of the other antigen. Sera from group O people contain two separable antibodies, anti-A and anti-B and a cross-reacting antibody called anti-A, B (mostly IgG).\n\nImmunoglobulin class and complement-mediated lysis\n\nMost naturally occurring ABO antibodies are of the IgM class. This is a key difference from the immune antibodies produced by alloimmunization in pregnancy or after incompatible transfusion, which are typically IgG. ABO antibodies are mostly IgM but some IgG is present, and they efficiently fix complement. IgM is a pentameric molecule with a large number of antigen-binding sites, so it agglutinates red cells efficiently. Once bound, it activates the classical complement cascade, which can lead to the formation of membrane attack complexes and the lysis of incompatible red cells inside the circulation. This intravascular destruction is the basis of the severe acute hemolytic transfusion reactions associated with ABO mismatch. The antibodies are also most active at body temperature. They are serologically detectable through increases in titers, agglutinin avidity and hemolytic activity and have greater activity at 37ºC.\n\nImmune tolerance to the individual's own antigens\n\nAn individual does not make antibodies against the A or B antigen that is present on his or her own red cells. This self-tolerance is what distinguishes the natural antibodies from autoantibodies. Antibodies develop against whichever ABH antigens are absent on the person's own RBCs. Blood group AB is the clearest example: because both antigens are expressed, AB individuals produce neither antibody. Group AB individuals are believed not to have anti-A nor anti-B antibodies because they express both antigens on their red cells. The group A individual, by contrast, is thought to be tolerant to A antigen while responding to the B-like structures in the environment. The mechanism of tolerance has not been fully specified in the ABO context, but it is generally understood as a form of immune tolerance that prevents autoimmune attack on the body's own antigens.\n\nTiters across groups\n\nAntibody strength varies considerably among individuals. Studies of group O donors, the largest group in most cohorts, show that anti-A usually reaches higher titers than anti-B. Anti-A titers were significantly higher than anti-B titers for both IgM and IgG. IgG titers were significantly higher than IgM. Titers are also shaped by environmental factors. Females had higher antibody titers than males, and lower IgM and IgG levels were found in smokers versus non-smokers.\n\nGroup O individuals are the group in which the strongest responses are usually reported, since they carry both antibodies. Whereas individuals with blood type AB do not possess ABO antibodies in their serum, blood type O is associated with both anti-A and anti-B antibodies. A single Indian donor study reported that high-titer IgM (64 or more) was more prevalent in group O than in groups A and B, but this comparison rests on one cross-sectional sample and different denominators, so it should be treated as suggestive rather than definitive. Systematic comparisons of titers across all four groups remain limited, and the reasons why group O individuals show the highest titers are not established." }, { "heading": "Transfusion Medicine Applications", "text": "Compatibility rules\n\nRed cells and plasma are matched separately, because each component can carry a different set of ABO antibodies. Group O red cells carry neither A nor B antigen, so they can be given to recipients of any group. Group O erythrocytes are considered universal and may be used in all blood transfusions. Group A and group B red cells are restricted to recipients who share their group or are AB, and AB red cells go only to AB recipients. Plasma works in the opposite direction. Type AB donors are considered \"universal donors\" of plasma because their plasma does not contain anti-A or anti-B. Group O plasma, which contains both antibodies, is therefore restricted to group O recipients. A standard component matrix summarizes these rules, listing for each patient group which red cells and which plasma are acceptable.\n\nThese \"universal\" labels are simplifications. Some transfusion researchers argue that the traditional view, in which group O red cells, group AB plasma and any-group platelets are equally safe, is outdated according to recent data from many clinical settings.\n\nPre-transfusion testing\n\nCompatibility is confirmed before each transfusion through several steps. Forward typing tests the patient's red cells with commercial anti-A and anti-B reagents. Reverse typing tests the patient's plasma against reference red cells of known group. The two results should agree. ABO discrepancies occur when the results of forward and reverse blood typing do not match, leading to uncertainty in determining a patient's actual blood group. Such discrepancies can come from technical error, weak antigen expression, unexpected antibodies, or a recent transfusion. Antibody screening then checks for clinically significant antibodies to other blood group systems, and crossmatching mixes the recipient's serum with the donor's red cells before the unit is issued.\n\nPlatelets and plasma-containing components\n\nPlatelets express ABO antigens far less abundantly than red cells, so the main risk from platelet products comes from the plasma they are suspended in, not from the platelets themselves. Plasma from a group O donor can contain high-titre anti-A and anti-B, and when such platelets are given to a non-O patient, they can cause hemolysis. An early case involved a group A1 patient who developed transient hemolysis after receiving platelets pooled from four group O donors, two of whom had anti-A titres of 1:10240. The use of minor ABO-incompatible platelets is associated with risk of a hemolytic transfusion reaction because of the presence of naturally occurring anti-A or anti-B. Major incompatibility, by contrast, is linked mainly to reduced platelet recovery. Blood services manage this risk by preferring plasma-compatible or low-titre products. Low-titre anti-A/B apheresis platelets or pooled platelets pose a lower risk of haemolysis when transfusing ABO incompatible components. Surveys of hospital laboratories suggest, however, that most do not include a method to limit the risk of hemolysis when such platelets must be used.\n\nSeverity and clinical significance\n\nThe ABO system is generally regarded as the most important blood group in transfusion practice. The ABO system is regarded as the most important blood group system in transfusion medicine because of severe hemolytic Transfusion Reactions and, to a lesser degree, Hemolytic Disease of the Newborn. The reason lies in the strength of the naturally occurring antibodies. Hemolysis is most common and most severe when recipient plasma antibodies attack donor red cells. More than 80% of acute hemolytic transfusion reactions are caused by ABO incompatible RBC transfusions, and although fewer than 10% of ABO-incompatible transfusions are fatal, mortality rises with larger volumes and with delays in recognizing the reaction. Severity also depends on the recipient's condition. The severity of an acute hemolytic transfusion reaction depends on the degree of incompatibility, the amount of blood given, the rate of administration, and the health of the kidneys, liver, and heart. Most such reactions are not caused by biology but by administrative error, since most AHTRs are the result of clerical errors, because the antibodies involved are easy to detect." }, { "heading": "Transplantation, Stem Cells and Pregnancy", "text": "Solid organ transplantation\n\nFor nearly three decades, ABO-incompatible organ transplantation was avoided. Anti-A or anti-B isoagglutinins bound to the graft's vascular lining, activated complement, and drew in platelets and mononuclear cells, which formed microthrombi and occluded vessels. The result was hyperacute or acute humoral rejection and graft loss. The first hints that not all such antibodies were harmful came from successful ABO-incompatible liver transplants, and an ABO-incompatible bone marrow graft succeeded once the recipient's ABO antibodies had been removed beforehand.\n\nCurrent practice treats ABO incompatibility as a problem to be managed rather than a contraindication, mainly in living-donor kidney transplantation. Desensitization combines extracorporeal antibody removal, usually therapeutic plasma exchange or immunoadsorption, with B-cell-directed therapy such as rituximab and triple immunosuppression. Immunoadsorption columns that remove isoagglutinins without targeting a specific blood group antigen have been reported as equally effective and less costly. The most widely cited benchmark is a pretransplant anti-A/anti-B titer of 1:8 or lower. One study found that the standard plasma exchange and IVIG protocol, without B-cell depletion, worked as well as protocols that added B-cell depletion. Pre-existing titers above about 256 have been linked to a high risk of antibody-mediated rejection. Post-transplant rebound of isoagglutinins is a major risk factor for that rejection, yet a rebound that occurs after the early postoperative period often does no lasting harm to the kidney, a phenomenon called accommodation whose mechanism remains poorly understood. The main concern is infection: in Collaborative Transplant Study data, roughly one additional death from infection occurred in the first year per 100 ABO-incompatible kidney recipients. In a single-centre comparison of 34 desensitized recipients with 68 matched compatible recipients, graft survival did not differ significantly, but patient survival showed a non-significant trend toward lower values, and BK virus replication, nephropathy and colonization with multidrug-resistant bacteria were more frequent.\n\nHematopoietic stem cell transplantation\n\nIn hematopoietic stem cell transplantation, the direction of incompatibility determines the complications. In major incompatibility, the recipient's plasma antibodies attack donor red cells, and pure red cell aplasia and delayed hemolysis can follow. In minor incompatibility, isohemagglutinins in the donor plasma attack recipient red cells, often causing immediate but usually mild hemolysis during infusion, which can be reduced by removing donor plasma from the graft. A distinct delayed complication, passenger lymphocyte syndrome (PLS), occurs when donor B lymphocytes carried in the graft produce antibodies against recipient red cells. It is classified as a rare subtype of graft-versus-host disease and typically appears in the second week after transplantation, often between about day 5 and day 15. Most cases are mild and self-limiting, with the donor-derived antibodies disappearing within months, but severe intravascular hemolysis and disseminated intravascular coagulation have been reported. Blood bank practice is not standardized: a survey of hospitals found that most gave crossmatch-compatible group O red cells to recipients of groups A, B or AB, yet mild PLS still occurred in several of them. Monitoring typically tracks lactate dehydrogenase, bilirubin, blood counts and the direct antiglobulin test, and management may include plasma reduction, immunoadsorption or plasma exchange. ABO-incompatible transplants account for roughly 30% of related-donor and up to 50% of unrelated-donor transplants, so these issues are common.\n\nPregnancy and hemolytic disease of the newborn\n\nBecause group O individuals make IgG anti-A and anti-B, a group O mother carrying an A, B or AB fetus can transfer these antibodies across the placenta. This causes hemolytic disease of the newborn (HDN). With the decline of Rh-related disease, ABO incompatibility has become the most frequent cause of HDN, and it can occur in a first pregnancy because the mother's antibodies arise without prior sensitization. Only IgG antibodies pass the placenta, yet they are found in the circulation of most newborns of group O mothers.\n\nABO HDN is generally milder than Rh disease for several reasons. A and B antigens are weakly expressed on neonatal red blood cells compared with adult cells, which limits the target available to maternal antibodies. ABO antigens are also present on many fetal tissues, so a portion of the transferred antibody binds elsewhere. Most affected infants develop mild jaundice that responds to phototherapy, while severe cases requiring exchange transfusion or intravenous immunoglobulin are reported only occasionally.\n\nPre-transplant and prenatal screening\n\nBefore transplantation, clinicians determine the donor and recipient ABO groups and measure anti-A and anti-B titers, usually by serial dilution, to decide whether desensitization is needed and when the titer is low enough to proceed. Titration methods are not yet standardized across centres, and expert consensus has not settled the best management approach. After transplantation, serial titers guide decisions about further plasma exchange or immunoadsorption.\n\nIn pregnancy, screening focuses on maternal anti-A/anti-B IgG titers in group O women. A recent case-control study of group O, Rh-positive mothers reported that combining these titers with maternal soluble VE-cadherin gave good discrimination for ABO HDN, although such results need confirmation in larger cohorts. Some authors have argued for antenatal antibody screening of all mothers regardless of Rh status, so that cases can be identified early." }, { "heading": "Associations with Disease", "text": "Cardiovascular and thrombotic findings\n\nThe most consistently replicated disease link concerns thrombosis. Blood group non-O (A, B, and AB) individuals have consistently been found to demonstrate increased incidence of both arterial and venous thrombotic disease, compared to group O individuals. The leading explanation runs through von Willebrand factor (VWF). The rate of proteolytic clearance of VWF by ADAMTS-13 is relatively lower in non-O plasma, which lengthens the VWF half-life. As a result, VWF levels were 25–30% higher in non-O plasma than in group O plasma. Because VWF also protects factor VIII from breakdown, high VWF in non-O plasma also tends to raise FVIII levels.\n\nThe size of the venous-thrombosis effect depends on study design. A meta-analysis of case-control studies gave a pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38) for non-O status. A prospective cohort, the Longitudinal Investigation of Thromboembolism Etiology, produced a lower estimate: compared with O blood type, the age-adjusted OR of VTE for non-O blood type was 1.64 (95% CI, 1.32–2.05). In a Scandinavian blood-donor cohort of about 1.5 million people, the relative risks were comparatively modest, but the incidence differences translated to generally high population attributable fractions, exceeding 30% for VTEs. The same LITE analysis found an interaction with factor V Leiden: the combined OR was 6.77 (95% CI, 3.65–12.6), which is more than the product of the separate effects.\n\nCancer associations\n\nA large systematic review of observational studies included 89 eligible studies that reported 100,554 cases at 30 cancer sites. Across all cancers, the pooled OR was 1.12 (95%CI: 1.09-1.16) for A vs. non-A groups, and 0.84 (95%CI: 0.80-0.88) for O vs. non-O groups. At individual sites, blood group A was found to confer increased risk of gastric cancer (OR=1.18; 95%CI: 1.13-1.24), pancreatic cancer (OR=1.23; 95%CI: 1.15-1.32). The gastric association has been tested in a single large dataset: a Shanghai case-control study compared 1045 cases of gastric cancer, whereby the patient underwent a gastrectomy in Ruijin Hospital, Shanghai with blood donors, and found that the risk of gastric cancer in blood group A was significantly higher than that in non-A groups (O, B and AB).\n\nFor pancreatic cancer, the strongest evidence comes from two prospective US cohorts of about 107,500 health professionals, in which individuals with blood types A, B, or AB exhibit a significantly increased risk of developing pancreatic cancer compared to those with blood type O, with hazard ratios of 1.32, 1.72, and 1.51. Survival data point in a related direction: a meta-analysis found that blood type O showed better OS than non-O in both unadjusted (HR 0.82; 95 % CI 0.75–0.91) and adjusted analyses (HR 0.76; 95 % CI 0.68–0.85). Prognostic findings are not uniform, however. For gastric cancer, one meta-analysis concluded that ABO blood groups may not be prognostic for patients with gastric cancer.\n\nInfection associations\n\nInfection studies have mostly concerned SARS-CoV-2. A 2021 meta-analysis of 14 observational studies found that group O subjects were seen to have decreased odds of contracting COVID-19 infection (OR: 0.78, 95%Cl: 0.68 – 0.89, P=0.0003). Its findings on severity and death were weaker: no significant association was found between ABO blood groups and COVID-19 severity and mortality. Individual studies disagree. A single-centre study of 128 critically ill patients reported that an association between A and AB blood type with more severe COVID-19, while other reports describe inconsistent findings across all studies and the underlying mechanisms remain unclear.\n\nOther pathogens have also been examined. Earlier work linked blood groups to certain blood groups and various disease susceptibilities (for example Hep B virus, Norwalk virus, or bacterial diseases like H. pylori), and the gastric-cancer studies above were often framed around Helicobacter pylori infection as a possible intermediate. Older reports on cholera and malaria, which are often cited as evidence for pathogen-driven selection, are discussed in the section on population genetics and are not repeated here.\n\nPhenome-wide studies and statistical caveats\n\nLarge biobank and registry analyses test one genotype or blood group against many outcomes at once. This approach can detect new associations, but it multiplies the number of statistical tests, so nominal p-values must be corrected for multiple comparisons before they are interpreted. The effect sizes reported in these studies are usually small, with odds ratios typically between about 1.1 and 2. Such modest effects are sensitive to differences in age, sex, ancestry and sampling, and they often disappear when studies with different designs are compared. Interpreting these associations therefore requires attention to confounding, to whether the link is causal, and to whether a finding replicates in independent populations." }, { "heading": "Typing Methods and Standardization", "text": "Serological typing\n\nRoutine ABO grouping is still largely done by agglutination. In the direct test, test red blood cells bearing an antigen agglutinate in the presence of the reagent containing the corresponding antibody, so visible clumping shows that the matching antigen is on the red cells. Because a single test can mislead, the result is usually cross-checked against the plasma: the presence of the corresponding antibodies in the plasma is verified using known red blood cells A1, B and, possibly, A2 and O.\n\nEarly reagents were derived from human blood, which made their supply and consistency difficult to control (typing relied on human polyclonal anti-A and anti-B sera, and developers sought standardized reagents that could be supplied in unlimited quantities). Monoclonal cocktails replaced these reagents in the 1990s. Current commercial anti-A and anti-B reagents are murine monoclonal IgM antibodies. Because single clones can miss weak subgroups, manufacturers blend two antibodies to optimise the intensity of agglutination and the potency for detecting weaker subgroups, and an anti-A,B reagent is used to catch some weak A and B variants that the single-specificity reagents miss in detecting some weak subgroups of A and B.\n\nInterpretation has known pitfalls. Anti-B does not agglutinate \"acquired B\" red cells, and weak phenotypes, transfusion recipients, mosaics and chimeras can all complicate a result (in transfusion recipients, certain weak phenotypes A or B, hemopathological modifications, mosaics or chimeras).\n\nMolecular genotyping\n\nGenotyping reads the ABO gene itself. The gene lies on chromosome 9 at 9q34 and has seven exons that span >19 kb of genomic DNA, and the largest part of the open reading frame is located on exons 6 and 7, which encode the catalytic domain of the glycosyltransferase (mutations critical for ABO blood group phenotypes have predominantly been found in exons 6 and 7). Early assays therefore targeted these exons. One PCR-RFLP method used restriction enzymes to distinguish six common alleles and seven of the less frequent alleles.\n\nScreening for rare alleles is more demanding. One study built a panel of 102 different PCRs, each specific for a single nucleotide variation and tested 109 individuals; in 19 cases the results were inconsistent with serology, and sequencing revealed new alleles. High-throughput work has since used sequencing of exons 6 and 7 at scale, typing 1.69 million samples and describing 287 unique novel variants in exons 6 and 7. Still, exon 6 and 7 methods can miss non-deletional O, hybrid, or new alleles, which is why longer-range sequencing covering regulatory and intronic regions has been developed. For this reason, one case report recommends dual serological and molecular biological testing when typing is complex.\n\nNomenclature and ISBT numbering\n\nThe ABO system is standardized by the International Society of Blood Transfusion (ISBT). The ISBT Working Party was established in 1980 to develop a numerical terminology based on blood group genetics. Under this scheme, the number \"001\" and symbol \"ABO\" designate the ABO blood group system, and the A antigen is written as 001001 or ABO:1. The ISBT publishes its table of systems regularly; the version dated May 2025 lists ABO at 9q34.2. Reviews give differing totals for recognized systems, from over 30 to 43.\n\nThe ABO system once included an additional antigen. Originally the ABO system contained five antigenic determinants, but the ABO5 antigen was made obsolete after the H antigen was removed to form the H system in 1990. The H antigen, the precursor on which ABO antigens are built, now has its own entry, H (ISBT H 018), and is not part of the ABO system (ISBT ABO 001).\n\nRelationship with the Rh and other systems\n\nABO is one of the most clinically important systems; the ABO and the Rh blood group systems are the most clinically significant blood group systems. The Rh system was described in 1940 by Karl Landsteiner and Alexander Wiener, who produced an antiserum in animals immunized with rhesus monkey red cells. Genetically, Rh lies elsewhere: Rh is on chromosome 1p36.11 and carries C, c, D, E and e antigens, while MNS is on 4q31.21 and Kell is on 7q34. A practical difference is antibody class: ABO antibodies mainly elicit IgM antibody reactions, whereas Rh antibodies are usually immune-type antibodies formed after exposure." }, { "heading": "Open Questions and Research Debates", "text": "Causation, confounding or chance\n\nMany ABO–disease associations have been reported, but few have been shown to reflect direct biology. A large Danish registry study of 482,914 patients found that the incidence rate ratios of 101 phecodes were statistically significant between the ABO blood groups. Its authors, however, stressed that the retrospective inclusion of individuals after an in-hospital blood group test compromises any causal reading. Agnostic screens of this kind also show that most of the investigated disease or disease groups do not seem to be strongly influenced by the ABO blood group of the individual. Some apparent links may be secondary. For example, an association between group A and diabetes or hyperlipidemia may arise because those conditions are routinely diagnosed in patients with ischemic heart disease, which group A is also linked to (epidemiological detection bias).\n\nConfounding is a persistent concern. ABO allele frequencies vary significantly across ethnic groups, and confounders such as race, socioeconomic status and comorbidities may influence research findings. Even well-adjusted cohorts can retain residual bias. A UK Biobank analysis, for instance, did not reproduce an earlier stroke association, which its authors partly attributed to selection bias among older participants, and it noted that some confounding due to the geographical distribution of blood groups in Great Britain remains possible. Chance is a serious alternative in phenome-wide scans, which run very large numbers of tests and therefore require stringent correction for multiple comparisons. The strongest case is pancreatic cancer: a large prospective cohort reported that non-O blood groups (A, AB and B) were significantly associated with elevated pancreatic cancer risk, with hazard ratios of 1.32, 1.51 and 1.72, respectively, and a locus within the ABO gene was replicated in an independent case–control sample.\n\nWhy the polymorphism has been maintained\n\nWhy ABO variation has persisted for so long remains unresolved. Classical heterozygote advantage, the mechanism behind sickle-cell variation and malaria, is considered an unlikely explanation for such long-lived balancing selection. One primate study argued that heterozygote advantage would more plausibly give only a transient solution, and it noted that single \"cis-AB\" alleles that create the AB phenotype have not reached fixation in any surveyed species and are rare in humans. The same work concluded that ABO variation probably reflects a multiallelic balanced polymorphism, with cryptic differences in function among A and B alleles, meaning the A, B and O labels may not capture all the variation that selection acts on. A further point is that the polymorphism is found across many primates, while red-cell expression of these antigens is restricted to hominoids, so the selected trait may not be the red-cell antigen itself.\n\nCandidate pathogens fall into several groups. For malaria, laboratory work showed that human macrophages in vitro and mouse monocytes in vivo phagocytose P. falciparum-infected O erythrocytes more avidly than infected A and B erythrocytes, providing a plausible mechanism, while genetic studies have linked common ABO variation to susceptibility to severe Plasmodium falciparum malaria. Evidence for cholera is more contested. Reports suggested that O individuals more often had severe infection by some Vibrio cholerae strains, but such findings are small and have not been consistently replicated. Methodology is also a limit: known causal genes such as ABO overlap poorly with genome-wide selection scans, and existing tests may be underpowered to detect these true positives. In short, the case for pathogen-driven selection rests on mechanistic and candidate-gene evidence rather than on demonstrated population-level selection, and the question of which pressures dominate remains open.\n\nBiological roles outside red cells\n\nABO antigens are also expressed on plasma proteins, which raises the question of whether they do anything functional. The best-studied case is von Willebrand factor (VWF). ABO(H) carbohydrate antigenic determinants are expressed on the N-linked glycan chains of circulating plasma VWF. Group O individuals have lower VWF levels; one review put the difference at about 25 percent higher in non-O compared to group O individuals. The proposed mechanisms include altered clearance and proteolysis, since blood group O VWF demonstrates enhanced susceptibility to ADAMTS13 proteolysis. In a large cohort, ABO explained a substantial share of VWF variation but a much smaller direct share of factor VIII activity, which suggests that the effect runs largely through VWF rather than through factor VIII itself. Experiments on transplant recipients also suggested that platelet-derived VWF lacks ABO antigens, implying that the antigens are added to VWF made by endothelial cells. Platelets express ABO antigens on glycoproteins, and a small minority of donors (roughly 5–10%) show unusually high or low platelet expression, but the functional consequences of this variation are unclear. Whether the sugar chains themselves drive these effects, or whether linked genetic variants do, is still debated.\n\nReplication problems and inconsistent results\n\nReproducibility is a recurring problem, particularly for infectious diseases and cancers. For COVID-19, a genetic study found a signal at the chromosomal region containing ABO, yet the association between blood groups and the severity of the disease is still unclear. Reported susceptibility also varies by population: one cohort study found the highest mortality in group A patients, while it notes that in South-East Asia, where groups O and B predominate, comparable data were lacking. A recent review summarized the COVID-19 relationship as highly diverse and context-dependent. Endometrial cancer shows similar uncertainty, as evidence regarding the association between ABO blood type and endometrial cancer remains inconclusive. Cardiovascular findings are also mixed: a large Chinese hospital cohort reported a lower risk of isolated congenital heart disease in group A, but its authors noted that more studies need to be done.\n\nTaken together, these inconsistencies point to several recurring issues: small effect sizes, differences in ancestry and sample composition, and unequal control of socioeconomic and clinical confounders. Researchers have therefore called for analyses that repeat the analysis when suitable studies more representative of the global population become available. Whether ABO is a meaningful determinant of common disease, or whether its apparent role is an artifact of population structure, will depend on replication across diverse populations and on experimental work that identifies the biological mechanisms involved." } ], "links": [ "antigen", "erythrocyte", "antibody", "chromosome", "genetics", "evolution", "epidemiology", "cardiovascular-disease", "cancer", "infectious-disease", "carbohydrate", "gene", "allele", "phenotype", "immunoglobulin-g", "protein", "molecule", "enzyme", "cell-membrane", "exon", "mutation", "platelet", "polymerase-chain-reaction", "dna-sequencing", "gene-flow", "genetic-drift", "immune-tolerance", "autoimmunity", "complement-system", "virus", "bacteria", "confounding", "causation" ], "sources": [ { "title": "Blood Group ABO System - an overview", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-group-abo-system" }, { "title": "The ABO blood group - Blood Groups and Red Cell Antigens - NCBI Bookshelf", "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK2267/" }, { "title": "ABO, H, and Lewis Systems - Human Blood Groups - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1002/9781118493595.ch2" }, { "title": "Blood group systems - Smart - 2020 - ISBT Science Series - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/voxs.12593" }, { "title": "Blood Group Terminology", "url": "https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-group-terminology.html" }, { "title": "Blood Group - an overview", "url": "https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/blood-group" }, { "title": "Assessment of Minor Blood Group System Antigens and Their Phenotype among Voluntary Blood Donors in Ethiopian Blood and Tissue Bank Service, Addis Ababa, Ethiopia", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11111197/" }, { "title": "The Distribution Patterns of Rhesus (Rh) Antigens", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251307/" }, { "title": "ABO blood group system", "url": "https://en.wikipedia.org/wiki/ABO_blood_group_system" }, { "title": "Blood group systems - Smart - 2008 - ISBT Science Series - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/j.1751-2824.2008.00188.x" }, { "title": "ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9860303/" }, { "title": "[Karl Landsteiner (1868–1943) and the discovery of blood groups]", "url": "https://www.researchgate.net/publication/233998297_Karl_Landsteiner_1868-1943_and_the_discovery_of_blood_groups" }, { "title": "Karl Landsteiner • LITFL • Medical Eponym Library", "url": "https://litfl.com/karl-landsteiner/" }, { "title": "Discovery of Human Blood Groups", "url": "https://www.ebsco.com/research-starters/history/discovery-human-blood-groups" }, { "title": "Karl Landsteiner", "url": "https://www.ebsco.com/research-starters/biography/karl-landsteiner/" }, { "title": "Karl Landsteiner (1868–1943)", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077641/" }, { "title": "Karl Landsteiner (1868–1943): A Versatile Blood Scientist", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458791/" }, { "title": "Emil Freiherr von Dungern (1867–1961).", "url": "https://www.researchgate.net/figure/Emil-Freiherr-von-Dungern-1867-1961_fig2_230593236" }, { "title": "Ludwig Hirschfeld (1884– 1954).", "url": "https://www.researchgate.net/figure/Ludwig-Hirschfeld-1884-1954_fig3_230593236" }, { "title": "Ludwik and Hanka Hirszfeld: Pioneers in Blood Typing", "url": "https://www.kumc.edu/school-of-medicine/academics/departments/history-and-philosophy-of-medicine/archives/wwi/essays/biography/hirszfelds.html" }, { "title": "(PDF) Ludwik Hirszfeld: A pioneer of transfusion and immunology during the world wars and beyond", "url": "https://www.researchgate.net/publication/355982186_Ludwik_Hirszfeld_A_pioneer_of_transfusion_and_immunology_during_the_world_wars_and_beyond" }, { "title": "The Nobel Prize in Physiology or Medicine 1930 - Speed read: Blood relations - NobelPrize.org", "url": "https://www.nobelprize.org/prizes/medicine/1930/speedread/" }, { "title": "Entry - #616093 - BLOOD GROUP, ABO SYSTEM", "url": "https://omim.org/entry/616093" }, { "title": "Pseudo-Random Mating with Multiple Alleles", "url": "https://www.cambridge.org/core/journals/twin-research-and-human-genetics/article/pseudorandom-mating-with-multiple-alleles/CFF2162DF831F01842D0478FC8C741F8" }, { "title": "Fucosylated oligosaccharides for prevention of coronavirus infection", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11331329" }, { "title": "H Antigen - an overview", "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/h-antigen" }, { "title": "Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241692/" }, { "title": "[Molecular background of the ABO blood group system] - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/18202596" }, { "title": "ABO (Gene) - an overview", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/abo-gene" }, { "title": "ABO Blood Group System - an overview", "url": "https://www.sciencedirect.com/topics/immunology-and-microbiology/abo-blood-group-system" }, { "title": "Allele‐specific long‐range sequencing as a method for ABO haplotyping in clinical blood group diagnosis and immunohematology research - Matzhold - 2024 - Molecular Genetics & Genomic Medicine - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/mgg3.2286" }, { "title": "Nucleotide sequence variation in the ABO glycosyltransferase gene", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5763184" }, { "title": "ABO blood group A transferase and its codon 69 substitution enzymes synthesize FORS1 antigen of FORS blood group system", "url": "https://www.nature.com/articles/s41598-019-46029-7" }, { "title": "Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor", "url": "https://www.nature.com/articles/s41598-020-75462-2" }, { "title": "Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591562/" }, { "title": "Monosaccharides in Blood Types: Antigens & Biochemistry - Creative Biolabs", "url": "https://www.creative-biolabs.com/glycoprotein/monosaccharide-and-blood-types.htm" }, { "title": "ABO Blood Group System - an overview", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/abo-blood-group-system" }, { "title": "Blood Group Oligosaccharides: Antigens and Biosynthesis - Creative Biolabs", "url": "https://www.creative-biolabs.com/glycoprotein/blood-group-oligosaccharides.htm" }, { "title": "ABO blood group as a model for platelet glycan modification in arterial thrombosis - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4521621/" }, { "title": "A Distinct Approach for Molecular ABO Typing: A Case of Serology-Genotype Discrepancy Within a Family - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13540397/" }, { "title": "ABO Blood Group System - an overview", "url": "https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/abo-blood-group-system" }, { "title": "Deceased donor ABO discrepancy due to a rare AwB subgroup: Implications for organ allocation - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13158325/" }, { "title": "Frontiers", "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608716/full" }, { "title": "Entry - *110300 - ABO GLYCOSYLTRANSFERASE", "url": "https://www.omim.org/entry/110300" }, { "title": "An ABO blood grouping discrepancy: Probable B(A) phenotype - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1473050217300848" }, { "title": "Identification and analysis of a novel A allele with a c.565A > G variant on the ABO*A1.02 allele leading to subtype A: A case report", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746942/" }, { "title": "Serological characteristic and molecular basis of A2 subgroup in the Chinese population - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1473050212002030" }, { "title": "ABO (gene)", "url": "https://en.wikipedia.org/wiki/ABO_(gene)" }, { "title": "ABO ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase - NIH Genetic Testing Registry (GTR) - NCBI", "url": "https://www.ncbi.nlm.nih.gov/gtr/genes/28/" }, { "title": "ABO blood group system", "url": "https://www.ebsco.com/research-starters/health-and-medicine/abo-blood-group-system" }, { "title": "Genomic analysis of clinical samples with serologic ABO blood grouping discrepancies: identification of 15 novel A and B subgroup alleles", "url": "https://ashpublications.org/blood/article/98/5/1585/106072/Genomic-analysis-of-clinical-samples-with" }, { "title": "Establishing Blood Group Genotyping to Resolve ABO Discrepancies in Iran - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6646629/" }, { "title": "Cis-AB, the Blood Group of Many Faces, Is a Conundrum to the Novice Eye", "url": "https://www.annlabmed.org/journal/view.html?doi=10.3343%2Falm.2019.39.2.115" }, { "title": "Serological and genotyping study of rare cis-AB01/O01 in ...", "url": "https://www.sciedupress.com/journal/index.php/dcc/article/download/17645/10913" }, { "title": "Identification of five novel ABO blood group alleles - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/40221888/" }, { "title": "Haplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants", "url": "https://ashpublications.org/bloodadvances/article/7/6/878/486667/Haplotype-sequence-collection-of-ABO-blood-group" }, { "title": "Allele‐specific long‐range sequencing as a method for ABO haplotyping in clinical blood group diagnosis and immunohematology research - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10767447/" }, { "title": "Distribution of ABO and Rh Blood Groups and Allele Frequencies in the Bhutanese Population: A Retrospective Cross‐Sectional Study - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13088157/" }, { "title": "Gene frequencies of ABO and Rh(D) blood group alleles in Lagos, South-West Nigeria - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/pii/S1110863011000796" }, { "title": "Allele Frequency and Molecular Genotypes of ABO Blood Group System in a Jordanian Population", "url": "https://scialert.net/fulltext/?doi=jms.2007.51.58" }, { "title": "Polymorphisms and allele frequencies of the ABO blood group gene among the Jomon, Epi-Jomon and Okhotsk people in Hokkaido, northern Japan, revealed by ancient DNA analysis", "url": "https://www.nature.com/articles/jhg201090" }, { "title": "Evolutionay dynamics of the human ABO gene", "url": "https://www.researchgate.net/publication/51404345_Evolutionay_dynamics_of_the_human_ABO_gene" }, { "title": "Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/18003641/" }, { "title": "Three Signatures of Adaptive Polymorphism Exemplified by Malaria-Associated Genes", "url": "https://academic.oup.com/mbe/article/38/4/1356/5981112" }, { "title": "Blood ties: ABO is a trans-species polymorphism in primates", "url": "https://arxiv.org/pdf/1208.4613" }, { "title": "The ABO blood group is a trans-species polymorphism in primates", "url": "https://www.pnas.org/doi/full/10.1073/pnas.1210603109" }, { "title": "Primate ABO glycosyltransferases: evidence for trans-species evolution - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/8420836/" }, { "title": "Trans-species polymorphism in humans and the great apes is generally maintained by balancing selection that modulates the host immune response", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559023/" }, { "title": "The ABO blood group is a trans-spe ...", "url": "https://archive.connect.h1.co/article/717968835/" }, { "title": "Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria", "url": "https://academic.oup.com/hmg/article/17/4/567/2356221" }, { "title": "Environmental Correlation Analysis for Genes Associated with Protection against Malaria - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4839215/" }, { "title": "Normal Human Serum Contains Natural Antibodies Reactive With Autologous ABO Blood Group Antigens - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/pii/S000649712059472X" }, { "title": "Blood Group ABH Antigen - an overview", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-group-abh-antigen" }, { "title": "ABO Antibody Development, a New Look at a Very... : Transplantation", "url": "https://journals.lww.com/transplantjournal/fulltext/2023/11000/abo_antibody_development,_a_new_look_at_a_very_old.8.aspx" }, { "title": "Role of antibody screening in high titre group O donors - IP J Diagn Pathol Oncol", "url": "https://jdpo.org/archive/volume/8/issue/2/article/2821" }, { "title": "SciELO Brazil - Titers of ABO antibodies in group O blood donors Titers of ABO antibodies in group O blood donors", "url": "https://www.scielo.br/j/rbhh/a/sC6zjx7c6RCxVTgZCkDD64c/" }, { "title": "Analysis of Titers of Immunoglobulin M and Immunoglobulin G ABO Antibodies in Group O Blood and Plateletphersis Donors at a Tertiary Care Hospital - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13375045/" }, { "title": "The Evaluation of ABO Antibody Titers and Effect of Physical and Lifestyle Factors in Single Donor Platelets From O Blood Group Donors: A Cross-Sectional Study", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639193/" }, { "title": "Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9369710/" }, { "title": "Emergence and significance of carbohydrate-specific antibodies", "url": "https://www.nature.com/articles/s41435-020-0105-9" }, { "title": "ABO titers: harmonization and identifying clinically relevant ABO antibodies - Denomme - 2020 - Transfusion - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15726" }, { "title": "Journal of Clinical and Diagnostic Research (Feb 2024)", "url": "https://doaj.org/article/35256c6051db468aaed2083d9b0ded09" }, { "title": "Methods and compositions for immunomodulation", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869898" }, { "title": "The case against infusing ABO incompatible antibody and antigen from all blood components - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1473050226000340" }, { "title": "ABO blood group, ABO mismatched transfusions and leukoreduction of transfusions in hemostatic resuscitation studies", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443504/" }, { "title": "ABO Typing Discrepancies - StatPearls - NCBI Bookshelf - NIH", "url": "https://www.ncbi.nlm.nih.gov/books/NBK585061/" }, { "title": "Transfusion of Platelets Containing ABO-Incompatible Plasma: A Survey of 3156 North American Laboratories", "url": "https://meridian.allenpress.com/aplm/article/131/6/909/460225/Transfusion-of-Platelets-Containing-ABO" }, { "title": "Component compatibility", "url": "https://www.lifeblood.com.au/health-professionals/products/component-compatibility" }, { "title": "Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/17550318/" }, { "title": "ABO Grouping: Overview, Clinical Indications/Applications, Test Performance", "url": "https://emedicine.medscape.com/article/1731198-overview" }, { "title": "Blood Group Incompatibility - an overview", "url": "https://www.sciencedirect.com/topics/nursing-and-health-professions/blood-group-incompatibility" }, { "title": "Complications of Transfusion - Hematology - Merck Manual Professional Edition", "url": "https://www.merckmanuals.com/professional/hematology-and-oncology/transfusion-medicine/complications-of-transfusion" }, { "title": "Acute Hemolytic Transfusion Reaction - an overview", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/acute-hemolytic-transfusion-reaction" }, { "title": "Method for preparing universal plasma", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10357512" }, { "title": "Methods and compositions for immunomodulation", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11554141" }, { "title": "Blood component ABO Compatibility Chart", "url": "https://www.utmb.edu/bloodbank/blood-componenet-abo-compatability-chart" }, { "title": "Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/7089480" }, { "title": "Acute hemolytic transfusion reaction", "url": "https://en.wikipedia.org/wiki/Acute_hemolytic_transfusion_reaction" }, { "title": "Desensitization for solid organ and hematopoietic stem cell transplantation - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4237559/" }, { "title": "Desensitization for solid organ and hematopoietic stem cell transplantation - Zachary - 2014 - Immunological Reviews - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/imr.12150" }, { "title": "ABO-Incompatible Kidney Transplantation", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338156/" }, { "title": "Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption", "url": "https://hero.epa.gov/reference/3151435/" }, { "title": "Immunoadsorption-Based Desensitization With Column Reuse in ABO-Incompatible Living Donor Renal Transplantation", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811956/" }, { "title": "Laboratory approaches in desensitization for ABO-incompatible transplantation - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12521844/" }, { "title": "Passenger Lymphocyte Syndrome Following Minor ABO-incompatible Liver Transplantation: A Case Report - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/42144293/" }, { "title": "Expanding the spectrum of post-HSCT hemolysis: from passenger lymphocyte syndrome to host- and graft-associated alloimmune hemolytic anemia", "url": "https://link.springer.com/article/10.1007/s44313-026-00173-y" }, { "title": "Immuno-Hematologic Complexity of ABO-Incompatible Allogeneic HSC Transplantation", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11119197/" }, { "title": "Clinical Guide to ABO-Incompatible Allogeneic Stem Cell Transplantation - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/pii/S1083879113001456" }, { "title": "A survey of transfusion support strategies for passenger lymphocyte syndrome in minor ABO-mismatched allogeneic hematopoietic stem cell transplantation - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/42313380/" }, { "title": "Full article: Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion", "url": "https://www.tandfonline.com/doi/full/10.1080/16078454.2021.1986654" }, { "title": "Dual-biomarker strategy for prenatal prediction of ABO hemolytic disease: Maternal sVE-cadherin and anti-A/B IgG titer", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795030/" }, { "title": "Comparison of demographic characteristics and haematological parameters in newborns with and without haemolytic disease due to ABO incompatibility", "url": "https://link.springer.com/article/10.1186/s12887-025-05935-8" }, { "title": "Hemolytic Disease of Newborn due to ABO Incompatibility between B Blood Group Mother and A Blood Group Neonate - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10104695/" }, { "title": "The etiology of ABO hemolytic disease of the newborn - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/7191589" }, { "title": "Latest insights on ABO‐incompatible living‐donor renal transplantation", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004137/" }, { "title": "ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/17002642/" }, { "title": "ABO Blood Group and Thromboembolic Diseases", "url": "https://www.intechopen.com/chapters/80474" }, { "title": "Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews - NCBI Bookshelf", "url": "https://www.ncbi.nlm.nih.gov/books/NBK127288/" }, { "title": "ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/pii/S1538783622104526" }, { "title": "ABO Blood Group and Risk of Thromboembolic and Arterial Disease", "url": "https://www.ahajournals.org/doi/10.1161/circulationaha.115.017563" }, { "title": "ABO blood groups and risk of cancer: a systematic review and meta-analysis - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/24969898/" }, { "title": "ABO Blood Group System and Gastric Cancer: A Case-Control Study and Meta-Analysis", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497328/" }, { "title": "Association between ABO blood groups and pancreatic cancer outcomes: A systematic review and meta-analysis - ScienceDirect", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1424390325001152" }, { "title": "Review Article ABO blood groups and prognosis of gastric ...", "url": "https://e-century.us/files/ijcem/12/8/ijcem0095131.pdf" }, { "title": "ABO Blood Group is Associated with COVID-19 Susceptibility", "url": "https://scielo.isciii.es/pdf/ijm/v3n1/2695-5075-ijm-3-1-71.pdf" }, { "title": "ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964209/" }, { "title": "Effect of ABO blood group on the severity and clinico-pathological parameters of COVID-19", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11140347/" }, { "title": "ABO blood group and the risk of pancreatic cancer - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/19276450/" }, { "title": "129EN01 Oct-05-2017 BLOOD GROUPING REAGENTS Anti-A (ABO1) REF 210520", "url": "https://www.fda.gov/media/111228/download" }, { "title": "129EN03 PAGE 1 / 5 BLOOD GROUPING REAGENTS Anti-A (ABO1) REF 210520", "url": "https://www.fda.gov/media/72460/download" }, { "title": "A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/4857639" }, { "title": "Monoclonal blood group antibodies - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/2481540/" }, { "title": "MTS™ A/B/D Monoclonal and Reverse Blood Grouping Reagent", "url": "https://www.mycts.org/Portals/0/Assay_PI/WholeBlood/ABO%20Vision.pdf" }, { "title": "Rapid Identification of Seven Common ABO Alleles by Two-Dimensional Polymerase Chain Reaction Technology", "url": "https://karger.com/tmh/article/50/6/502/842162/Rapid-Identification-of-Seven-Common-ABO-Alleles" }, { "title": "Systematic analysis of the ABO gene diversity within exons 6 and 7 by PCR screening reveals new ABO alleles - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/12662274" }, { "title": "ABO genotyping by PCR-RFLP and cloning and sequencing - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/15648848/" }, { "title": "ABO allele-level frequency estimation based on population-scale genotyping by next generation sequencing", "url": "https://link.springer.com/article/10.1186/s12864-016-2687-1" }, { "title": "A Rapid Long PCR-Direct Sequencing Analysis for ABO Genotyping", "url": "https://www.annclinlabsci.org/content/41/4/340.full" }, { "title": "Identification and analysis of a novel A allele with a c.565A > G variant on the ABO*A1.02 allele leading to subtype A: A case report - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/41465921/" }, { "title": "Blood Group System - an overview", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-group-system" }, { "title": "Table of blood group systems v12.0 31-MAY-2025 Page 1 of 3 No. Systemname", "url": "https://www.isbtweb.org/static/3bbbd515-1bf4-4ef4-80e9858f10c2b1ab/05fe5f3a-9d47-4ed8-a3f8b297faf0c1a2/Tableofbloodgroupsystems.pdf" }, { "title": "Blood group systems", "url": "https://elearning.uniroma1.it/mod/resource/view.php?id=475917" }, { "title": "Human blood group systems", "url": "https://en.wikipedia.org/wiki/Human_blood_group_systems" }, { "title": "Human monoclonal antibody against group A red blood cells", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/4764465" }, { "title": "Streptomyces griseoplanus α-galactosidases for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells", "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7993896" }, { "title": "Associations of ABO and Rhesus D blood groups with phenome-wide disease incidence: A 41-year retrospective cohort study of 482,914 patients", "url": "https://elifesciences.org/articles/83116" }, { "title": "An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk", "url": "https://elifesciences.org/articles/65658" }, { "title": "Full article: A narrative review of the epidemiological and mechanistic associations between ABO blood groups and diseases: focusing on cardiovascular diseases, cancers, diabetes, malaria, COVID-19 and rheumatic diseases", "url": "https://www.tandfonline.com/doi/full/10.1080/07853890.2026.2710922" }, { "title": "A phenome-wide association study of ABO blood groups", "url": "https://link.springer.com/article/10.1186/s12916-020-01795-4" }, { "title": "The ABO blood group is a trans-species polymorphism in primates", "url": "https://www.pnas.org/doi/10.1073/pnas.1210603109" }, { "title": "ABO Blood Groups Influence Macrophage-mediated Phagocytosis of Plasmodium falciparum-infected Erythrocytes", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469569/" }, { "title": "Genetic characterization of the ABO blood group in Neandertals", "url": "https://bmcecolevol.biomedcentral.com/articles/10.1186/1471-2148-8-342" }, { "title": "ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? - Jenkins - 2006 - Transfusion - Wiley Online Library", "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1537-2995.2006.00975.x" }, { "title": "The relationship between ABO blood group, von Willebrand factor, and primary hemostasis", "url": "https://ashpublications.org/blood/article/136/25/2864/461790/The-relationship-between-ABO-blood-group-von" }, { "title": "Association of ABO blood group with COVID-19 severity, acute phase reactants and mortality", "url": "https://www.medrxiv.org/content/10.1101/2021.04.19.21255738.full.pdf" }, { "title": "Association between ABO Blood Group and Risk of Congenital Heart Disease: A 6-year large cohort study", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314383/" }, { "title": "Beyond immunohaematology: the role of the ABO blood group in human diseases - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3827391/" }, { "title": "A General Model of Negative Frequency Dependent Selection Explains Global Patterns of Human ABO Polymorphism", "url": "https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0125003" }, { "title": "ABO blood group and von Willebrand factor: biological implications - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/24945431" }, { "title": "Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects", "url": "https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132626" }, { "title": "ABO blood group is a determinant of von Willebrand factor protein levels in human pulmonary endothelial cells - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7279561/" }, { "title": "ABO Blood Group Antigens on Human Plasma von Willebrand Factor After ABO-Mismatched Bone Marrow Transplantation", "url": "https://ashpublications.org/blood/article-abstract/94/8/2895/116577/ABO-Blood-Group-Antigens-on-Human-Plasma-von?redirectedFrom=fulltext" } ], "license": "https://creativecommons.org/licenses/by/4.0/" }